NVS News - Candlesense

Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, today announced a collaboration with N...

Partnership

6 days ago

New Novartis ESC data highlights strength of cardiovascular portfolio

PRESS RELEASE

How does this data position Novartis against competitors in the cardiovascular space? What is the expected market reaction to the strengthened cardiovascular portfolio? How will the new ESC data affect Novartis' upcoming earnings forecasts?

Clinical trials

6 days ago

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

How will the trial results impact the valuation of Novartis' pipeline and overall corporate pipeline risk profile? Could this success lead to further investment or partnership opportunities for Novartis in the ITP space? What is the anticipated market size for ianalumab in ITP and how could it affect Novartis' market share?

Clinical trials

12 days ago

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's ...

What are the potential long‑term implications for Novartis' positioning in autoimmune and immunology markets? How does this development affect competitive dynamics with other biotech firms pursuing Sjögren's disease therapies? What is the likelihood of price volatility around the upcoming investor presentations or earnings calls where the results will be discussed?

Clinical trials

13 days ago

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR

How will analysts' consensus estimates and target price revisions adjust in response to this announcement? Are there any risks or potential setbacks (e.g., FDA review delays, safety concerns) that could mitigate the positive sentiment? What is the expected impact on Novartis' revenue growth trajectory over the next 3‑5 years if ianalumab is approved?

Clinical trials

13 days ago